Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 13th Annual LD Micro Main Event investor conference on December 15 at 9:40 a.m. PST. Gregory D. Gorgas, President and CEO, will present to a live virtual audience. The conference format includes a 10-minute presentation followed by a Q&A session. The Main Event takes place on December 14-15 on the Sequire Virtual Events platform. Artelo is focused on developing therapeutics targeting the endocannabinoid system, addressing unmet medical needs in various conditions such as cancer and pain.
- None.
- None.
LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 9:40 a.m. PST / 12:40 p.m. EST. Gregory D. Gorgas, Artelo’s President and CEO will be presenting to a live, virtual audience.
The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.
Register here: ve.mysequire.com/
The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.
View Artelo Biosciences’ profile here: https://www.ldmicro.com/profile/ARTL
Profiles powered by LD Micro
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
About LD Micro/SEQUIRE
LD Micro begam in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.
The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.
In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
Source: Artelo Biosciences via LD Micro
FAQ
When will Artelo Biosciences present at the LD Micro Main Event?
Who is presenting for Artelo at the LD Micro conference?
What is the purpose of the LD Micro Main Event?
Where can I register for the LD Micro Main Event?
What is Artelo Biosciences focused on developing?
